Clinical Trials Browser

Phase 1/2 × tislelizumab × Clear all

NCT03744468 2026-04-02

Study of Surzebiclimab (BGB-A425) and Alcestobart (LBL-007) in Combination With Tislelizumab in Advanced Solid Tumors

Phase 1/2 Completed

147 enrolled 74 charts

Other solid neoplasmThoracic

Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in

NCT07468071 2026-04-02

KontRASt-R

Phase 1/2 Not yet recruiting

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT05516914 2026-04-01

A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors

Phase 1/2 Completed

Neoplasms

NCT07502768 2026-03-31

EpiRev-NKT

Phase 1/2 Not yet recruiting

Recurrence, Lymphoma, Extranodal NK-T-Cell

NCT05982522 2026-03-27

IN10018 Combination Therapy in Previously-treated Solid Tumors

Phase 1/2 Withdrawn

Other solid neoplasm

Solid Tumor

NCT05661955 2026-03-20

A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors.

Phase 1/2 Active not recruiting

DermatologicGenitourinary

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Melanoma

NCT04699188 2026-03-18

KontRASt-01

Phase 1/2 Active not recruiting

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis, Colorectal Neoplasms

NCT04282018 2026-02-20

Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab

Phase 1/2 Completed

97 enrolled 43 charts

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT05651022 2026-01-13

Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors

Phase 1/2 Active not recruiting

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Colorectal Neoplasms

NCT04425070 2026-01-05

TOUCH

Phase 1/2 Terminated

Lymphoma, T-Cell, Peripheral, Lymphoma, Extranodal NK-T-Cell

NCT05886439 2025-12-08

LK101 Combined With PD-1 or PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer

Phase 1/2 Recruiting

Lung Neoplasms

NCT07244705 2025-11-24

A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC

Phase 1/2 Recruiting

Gastrointestinal

Disease, Colorectal Neoplasms

NCT05609370 2025-10-02

A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer

Phase 1/2 Active not recruiting

Gastrointestinal

Colorectal Neoplasms

NCT05267054 2025-09-15

Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab

Phase 1/2 Completed

53 enrolled 17 charts

Lymphoma, Neoplasms, Lymphoma, Large B-Cell, Diffuse

NCT05632939 2025-09-10

ASKB589 in Combination With CAPOX and PD-1 Inhibitors in Patients With Advanced, and Unresectable G/GEJ Cancer.

Phase 1/2 Active not recruiting

Gastrointestinal

Stomach Neoplasms

NCT07025850 2025-08-01

Efficacy Study of Digoxin Combined With Serplulimab and Chemotherapy in First-Line Treatment of MSS Advanced Colorectal Cancer

Phase 1/2 Not yet recruiting

Gastrointestinal

Colorectal Neoplasms

NCT05978102 2025-07-23

A Dose Escalation and Dose Expansion Clinical Study of STI-7349 in Subjects With Advanced Solid Tumors

Phase 1/2 Recruiting

Other solid neoplasm

Advanced Solid Tumor

NCT04577963 2025-07-14

A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors

Phase 1/2 Terminated

52 enrolled 23 charts

BreastGastrointestinalGynecologic

Breast Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT04963088 2025-06-26

TALENT

Phase 1/2 Completed

Gastrointestinal

Stomach Neoplasms

NCT07010120 2025-06-13

A Clinical Trial of Neoadjuvant Targeted Therapy, Immunotherapy, and Lysogenic HSV-Based Virotherapy in Resectable Head and Neck Squamous Cell Carcinoma

Phase 1/2 Recruiting

Squamous Cell Carcinoma of Head and Neck

NCT04579757 2025-05-08

Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors

Phase 1/2 Terminated

87 enrolled 29 charts

EndocrineGastrointestinalHead & NeckNETSarcomaThoracic

Neoplasm Metastasis, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Neuroendocrine Tumors, Small Cell Lung Carcinoma, Thyroid Carcinoma, Anaplastic

NCT06030258 2025-04-30

IN10018 Combination Therapy in Treatment-naïve ES-SCLC

Phase 1/2 Recruiting

Small Cell Lung Cancer Extensive Stage

NCT06871527 2025-03-12

Fruquintinib Combined With PD-1 Inhibitor and FOLFOX as First-Line Treatment For Advanced Gastric Cancer

Phase 1/2 Not yet recruiting

Gastrointestinal

Stomach Neoplasms

NCT05319639 2025-02-27

Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab

Phase 1/2 Recruiting

Gastrointestinal

Stomach Neoplasms

NCT04666688 2025-02-12

LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors

Phase 1/2 Completed

GastrointestinalGenitourinaryHead & Neck

Bile Duct Neoplasms, Carcinoma, Transitional Cell, Colonic Neoplasms, Head and Neck Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Colorectal Neoplasms

NCT05431270 2025-01-31

Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 MAb, Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

Phase 1/2 Recruiting

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT04276493 2024-12-06

Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab

Phase 1/2 Completed

BreastGastrointestinal

Breast Neoplasms, Stomach Neoplasms

NCT03379259 2024-10-26

Study of BGB-A333 Alone and in Combination With Tislelizumab in Advanced Solid Tumors

Phase 1/2 Terminated

39 enrolled 29 charts

Other solid neoplasm

Advanced Solid Tumors

NCT03941873 2024-10-26

A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer

Phase 1/2 Completed

111 enrolled 22 charts

Gastrointestinal

Carcinoma, Carcinoma, Hepatocellular

NCT04068519 2024-10-26

Study Investigating Safety, Tolerability, Pharmacokinetics (PK) and Antitumor Activities of Anti-PD-1 (Programmed Death-1) Monoclonal Antibody

Phase 1/2 Completed

300 enrolled 23 charts

Other solid neoplasm

Advanced Solid Tumors

NCT06586099 2024-09-19

Tislelizumab with Azacitidine in the Treatment of R/R AML

Phase 1/2 Withdrawn

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT06471673 2024-08-26

A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer

Phase 1/2 Recruiting

Breast Neoplasms

NCT06456138 2024-06-13

Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC

Phase 1/2 Not yet recruiting

Neoplasms

NCT06394791 2024-05-01

Evaluation of The Efficacy And Safety of PD-1 + IL-2 Combined With Capox Treatment After Loop Colostomy Surgery in Left-sided Colorectal Cancer Patients Complicating Acute Obstruction

Phase 1/2 Not yet recruiting

Gastrointestinal

Left-sided Colorectal Cancer Complicating Acute Obstruction

NCT05581719 2024-04-17

A Phase 1/2a Study Evaluating Allocetra-OTS as Monotherapy or in Combination With Anti-PD-1 Therapy for the Treatment of Advanced Solid Tumor Malignancy

Phase 1/2 Terminated

Other solid neoplasm

Solid Tumor

NCT06303583 2024-03-12

CRIS

Phase 1/2 Enrolling by invitation

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT05842317 2024-02-09

Lenvatinib Plus Tislelizumab With or Without TACE in First-line Treatment of Unresectable HCC

Phase 1/2 Unknown

Gastrointestinal

Carcinoma, Hepatocellular

NCT05906524 2024-01-10

KD6001 in Combination With Anti-PD-1 Antibody±Bevacizumab in Patients With Advanced HCC and Other Solid Tumors

Phase 1/2 Unknown

Other solid neoplasm

Advanced HCC

NCT06022692 2023-09-05

HEAIS001

Phase 1/2 Completed

Gastrointestinal

Hyperthermia, Digestive System Neoplasms

NCT05982834 2023-08-09

Disitamab Vedotin, Fruquintinib and Tislelizumab in Second-line Treatment for HER2-positive MGC

Phase 1/2 Unknown

Gastrointestinal

HER2-positive Gastric Cancer

NCT05840835 2023-08-08

IMMINENT-01

Phase 1/2 Unknown

Other solid neoplasm

Advanced Solid Tumor

NCT05699811 2023-04-28

IFNα Expressing Mesenchymal Stromal Cells for Locally Advanced/Metastatic Solid Tumors

Phase 1/2 Recruiting

Other solid neoplasm

Locally Advanced or Metastatic Solid Tumors

NCT05833984 2023-04-27

Safety and Efficacy of IMM01 Plus Tislelizumab in Patients With Advanced Solid Tumors and Lymphomas

Phase 1/2 Unknown

LymphoidOther solid neoplasm

Solid Tumor

NCT04652440 2023-04-19

Ablation Combined With PD-1 in HCC: Phase II Study

Phase 1/2 Unknown

Gastrointestinal

Carcinoma, Hepatocellular

NCT05746728 2023-04-06

Surufatinib Combined With Tislelizumab in the Second-line and Further Treatment of Triple-negative Breast Cancer

Phase 1/2 Unknown

Triple Negative Breast Neoplasms

NCT04782804 2022-08-18

Adjuvant PD-1 Antibody in Combination With Capecitabine for Patients With ICC at High-Risk of Postoperative Recurrence

Phase 1/2 Unknown

Gastrointestinal

Cholangiocarcinoma

NCT05394415 2022-05-27

LATE

Phase 1/2 Unknown

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT04813107 2022-02-22

ANTICIPATE

Phase 1/2 Unknown

Muscle Invasive Bladder Cancer

NCT04979663 2021-08-09

GEMOX Combined With Donafenib and Tislelizumab in Biliary Tract Cancer

Phase 1/2 Unknown

Gastrointestinal

Biliary Tract Carcinoma

NCT04922047 2021-06-11

TACBIN-01

Phase 1/2 Unknown

Urinary Bladder Diseases, Urinary Bladder Neoplasms, Urogenital Neoplasms, Urologic Neoplasms